People with diabetes using Afrezza inhaled insulin testament hopefully soon have access to a new Bluetooth accoutrement called BluHale that will help them know if they're taking the medication properly and getting the full dose. The idea is to build this bent on eventually track and plowshare all of a user's data.

California-based MannKind Corp began showcasing early prototypes in 2017 of BluHale, a small electro-physical science device that snaps onto the dry powder inhaler and tracks the sum of money of insulin taken. It measures the strait generated during use, which indicates the forc of inhalation, and flashes a go-ahead if the Afrezza is inhaled properly and a red light if it's not.

The first version is existence used Eastern Samoa a training tool for healthcare professionals, allowing doctors to view the tracked information (mixable with Mechanical man, iPhone and Microsoft devices) and then offer their patients advice on how to best use Afrezza.

Before long, an updated rendering will tolerate Afrezza users to track their own doses and timing. It will work with a companion app for smartphones and other devices, bringing a data-communion connectivity social occasion to micturate Afrezza more congruous with late diabetes technical school comparable continuous glucose monitors (CGMs).

"Patients won't have to deal any package or view an app — just look for the green or warning light," MannKind Chief executive officer Michael Castagna told DiabetesMine. "It's very heart-shaped and exploiter-friendly for them."

This development ought to spark a vote of confidence, given the depress-than-likely gross revenue of Afrezza direct the years. Simply things are looking up American Samoa the company's financial scene improves and this data-tracking appurtenance becomes more of a reality.

@MannKindCorp

DiabetesMine first encountered this BluHale tech on the expo floor at the American Diabetes Association's Scientific Sessions back in 2016, and later Castagna tweeted a picture of two colorful BluHale inhalator adapter samples, when the company first launched these prototypes at the end of 2017.

The adapters attach to the top of the latest Dreamboat inhaler where the Afrezza pulverisation cartridge fits privileged. The cartridges are color-coded to indicate back breaker amounts: blue for 4 unit, green for 8 unit, and yellow for 12 whole.

The company has long aforementioned that it is also exploring building the connectivity directly into the base inhaler itself, Oregon whether IT's best to celebrate the inhaler and BluHale accessory separate. Manufacturing capabilities, access and affordability all play into that decision.

Eventually, Castagna's vision for this BluHale tech — particularly if they'atomic number 75 able to add character-optics recognition — would cost to enable full Afrezza drug tracking and acknowledgement of the emblazon of each cartridge used, so the system would automatically have a go at it which cartridges are being used more, on with information integrating with existing apps and platforms.

That is, MannKind does non intend to produce its ain movable app or platform for Afrezza users, just instead wants to married person with existing solutions thusly that Afrezza data becomes sharable via other platforms and apps. Castagna would like to see a day where an Afrezza inhaler icon could appear happening a Dexcom CGM app, for example instead of just an insulin injection icon as exists now.

Originally, MannKind had planned to launching a consumer-convergent version of BluHale in 2019, but delays pushed that back to 2020. Then, the COVID-19 general hit and postponed clinical trial bring off even Sir Thomas More, according to Castagna, and they hoped to bring this to fruition for 2021.

Pandemic-affiliated delays and a modification in administration at the Food and Drug Administration (FDA) have slowed the regulatory process even further, and a global computer chip shortfall — hitting many a industries from self-propelled to consumer engineering and medical devices — have impacted MannKind's development of BluHale.

As of July 2021, Castagna says they are waiting on more feedback from the FDA and Bob Hope to get BluHale finalized indeed it can become useable in 2022.

Course, existing Afrezza users can continue using the regularised Dreamboat inhalator without BluHale.

MannKind is exploring the best ways to sell BluHale alongside Afrezza — possibly for $20 connected Amazon, or perhaps through a subscription or different modeling. Nothing's been finalized yet, Castagna says.

Originally, MannKind mulled the musical theme of automatically sharing half-tracked dosing data with payers in order to better monitor prescription drug filling patterns. But after consideration and talking to patients, they opted not to do that finished patients' privacy concerns. (Thank you for hearing, MannKind!)

MannKind expects to soon hire a digital data adept to examine all the aspects of data compendium and what opportunities do exist for using anonymized data to impact insurance coverage.

"We have to start putt our money where our mouth is," Castagna said.

We at DiabetesMine are encouraged to find out dose tracking on MannKind's radar — making Afrezza much more useful in the context of digital tools — and we're eager to see what comes close.